Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected1
Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
(1) World Health Organization. Global Tuberculosis Report 2020. https://www.who.int/publications/i/item/9789240013131 (2) Kox. Tests for detection and identification of mycobacteria. How should they be used? Respir Med. 1995 Jul;89(6):399-408.; (3) Diel et al. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals. Eur Respir J. 2016 Feb;47(2):575-87.; (4) Behr et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444-9.
The Solution
Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients3
Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
Designed to provide the most accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
Accurate detection of mixed infections
(5) Jones M, et al. Xpert® MTB/RIF Ultra - design and analytical performance of a second generation Xpert® MTB/RIF assay. Poster presented at ECCMID. 2016 April 9-12, Amsterdam, Netherlands
The Impact
Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes4
Increased access to front-line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help limit community transmission5
Superior performance of Xpert MTB/RIF Ultra versus smear microscopy enables more people with MTB infections to be detected and treated earlier4
(7) Global Laboratory Initiative. GLI model TB diagnostic algorithms. Accessed Mar 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf; (8) World Health Organization. European Tuberculosis Laboratory Initiative. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologies. Accessed Mar 2017. http://www.euro.who.int/__data/assets/pdf_file/0006/333960/ELI-Algorithm.pdf; (9) Global Laboratory Initiative. Planning for country transition to Xpert® MTB/RIF Ultra cartridges. Accessed Apr 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_ultra.pdf
Related Products
Xpert HIV-1 Viral Load
Dual Target Detection for Extended Coverage and Superior Performance
Learn more
Xpert HBV Viral Load
Detection and quantitation of Hepatitis B virus (HBV) in less than one hour
Learn more
Xpert Xpress Flu/RSV
Accurate and reliable detection of Flu A, Flu B or RSV in as soon as 20 minutes*
Learn more
Xpert Xpress Strep A
Qualitative real-time PCR test providing accurate detection of Group A Streptococcus in as soon as 18 minutes.*
Learn more
Xpert HCV VL Fingerstick
Detection and quantitation of Hepatitis C virus (HCV) in about an hour
Learn more
Xpert HIV-1 Qual
Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in around 90 minutes
Learn more
Xpert Ebola
Accurate and Reliable Detection of Ebola Zaire Virus